NCT05156892View on ClinicalTrials.gov

Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

September 4, 2022

Primary Completion Date

January 1, 2026

Study Completion Date

January 1, 2027

Conditions
Ovarian Cancer
Interventions
DRUG

SUBA-itraconazole

150 mg BD

DRUG

Tamoxifen

"Dose Escalation:~Cohort 1: 20 mg OD Cohort 2: 40 mg OD Cohort 3: 60 mg OD~Dose-Expansion: Recommended dose from dose-escalation phase of study"

Trial Locations (1)

2010

Kinghorn Cancer Centre, St. Vincent's Hospital, Sydney

All Listed Sponsors
collaborator

Royal Prince Alfred Hospital, Sydney, Australia

OTHER

collaborator

Concord Hospital

OTHER

collaborator

Prince of Wales Hospital, Sydney

OTHER_GOV

collaborator

St Vincent's Hospital, Sydney

OTHER

lead

Anthony Joshua, FRACP

OTHER